Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.920
-0.140 (-6.80%)
At close: Feb 21, 2025, 4:00 PM
1.980
+0.060 (3.13%)
After-hours: Feb 21, 2025, 7:58 PM EST
Editas Medicine Employees
Editas Medicine had 265 employees as of December 31, 2023. The number of employees increased by 39 or 17.26% compared to the previous year.
Employees
265
Change (1Y)
39
Growth (1Y)
17.26%
Revenue / Employee
$233,053
Profits / Employee
-$794,611
Market Cap
158.49M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
EDIT News
- 5 weeks ago - Editas And Intellia: Strategic Shifts And Long-Term Investment Potential - Seeking Alpha
- 5 weeks ago - Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript) - Seeking Alpha
- 5 weeks ago - Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - GlobeNewsWire
- 6 weeks ago - Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Benzinga
- 2 months ago - Editas to reduce about 65% of its workforce over the next six months - Reuters
- 2 months ago - Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years - GlobeNewsWire
- 2 months ago - Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire